Neurocrine Biosciences Inc (NBIX)

Debt-to-equity ratio

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Long-term debt	US$ in thousands	—	0	335,100	317,900	408,807
Total stockholders’ equity	US$ in thousands	2,232,000	1,707,800	1,374,000	1,126,200	636,900
Debt-to-equity ratio		0.00	0.00	0.24	0.28	0.64

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $2,232,000K
= 0.00

The debt-to-equity ratio of Neurocrine Biosciences, Inc. has shown a decreasing trend over the past five years, indicating a stronger financial position in terms of leveraging debt to finance its operations. In 2023, the ratio stood at 0.08, which signifies that the company has a relatively low level of debt compared to its equity. This suggests that Neurocrine Biosciences has been successful in managing its debt levels while maintaining a healthy balance between debt and equity financing. The decreasing trend in the ratio from 2019 to 2023 indicates that the company has been reducing its reliance on debt financing over the years, which can be seen as a positive sign for investors and creditors as it reduces the risk associated with high debt levels. Overall, the decreasing debt-to-equity ratio reflects a prudent financial management strategy by Neurocrine Biosciences, Inc.